Related references
Note: Only part of the references are listed.Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
Lakshmi Nayak et al.
CLINICAL CANCER RESEARCH (2021)
The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Carmen Balana et al.
NEURO-ONCOLOGY (2020)
Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma A Randomized Clinical Trial
Roger Stupp et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2017)
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
Deborah T. Blumenthal et al.
NEURO-ONCOLOGY (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma
Michele Ceccarelli et al.
CELL (2016)
Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups
Michael Weller et al.
ACTA NEUROPATHOLOGICA (2015)
Mutational landscape and clonal architecture in grade II and III gliomas
Hiromichi Suzuki et al.
NATURE GENETICS (2015)
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
C. Balana et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Telomerase promoter mutations in cancer: an emerging molecular biomarker?
Joao Vinagre et al.
VIRCHOWS ARCHIV (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
TERT promoter mutations in primary and secondary glioblastomas
Naosuke Nonoguchi et al.
ACTA NEUROPATHOLOGICA (2013)
Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss
Hideyuki Arita et al.
ACTA NEUROPATHOLOGICA (2013)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Prognostic significance of telomerase-associated parameters in glioblastoma: effect of patient age
Daniela Loetsch et al.
NEURO-ONCOLOGY (2013)
Extended adjuvant temozolomide for treatment of newly diagnosed glioblastoma multiforme
Gloria B. Roldan Urgoiti et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3
Thierry Gorlia et al.
LANCET ONCOLOGY (2008)
Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma
P. Hau et al.
NEUROLOGY (2007)
MGMT methylation:: A marker of response to temozolomide in low-grade gliomas
Sibille Everhard et al.
ANNALS OF NEUROLOGY (2006)
Mechanisms of disease: Neural stem cells and the origin of gliomas
N Sanai et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Share Paper
